Evaluate the Safety and Clinical Activity of HH2853
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, first-in-human phase I dose escalation study. HH2853 will
be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
The accelerated titration (ATD) incorporated with Bayesian Optimal Interval design (BOIN)
will be used to assess the DLT, safety, tolerability, MTD and furthermore, to establish the
RP2D.